<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078723</url>
  </required_header>
  <id_info>
    <org_study_id>59978</org_study_id>
    <nct_id>NCT05078723</nct_id>
  </id_info>
  <brief_title>CYP2C19 Variants and Limonene Metabolism</brief_title>
  <official_title>Functional Consequences of CYP2C19 Variants on Limonene Metabolism in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine whether a non-invasive screening tool for CYP2C19 genetic&#xD;
      variants can be developed by measuring limonene metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytochrome P450 2C19 is an important enzyme that metabolizes many drugs. However, individuals&#xD;
      with genetic variants of CYP2C19, such as CYP2C19*2 and CYP2C19*3, are poor metabolizers of&#xD;
      these drugs. Therefore, it is of interest to determine whether the investigators can develop&#xD;
      a non-invasive assay to identify genetic variants of CYP2C19 by using a substrate for CYP2C19&#xD;
      found in citrus fruit, limonene. The purpose of the study is to examine changes in limonene&#xD;
      levels in human breath after drinking orange peel extract for people with CYP2C19*2 and&#xD;
      CYP2C19*3 genetic variants versus those that do not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Human volunteers participating in this study will be given an over the counter orange peel extract and limonene levels will be measured.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>We are using quantitative assays for this study which reduce the need for masking of the participant or investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Breath limonene value in parts per billion</measure>
    <time_frame>2 hours</time_frame>
    <description>The amount of limonene in the breath will be measured by mass spectrometry for each participant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CYP2C19 Genetic Variants</condition>
  <arm_group>
    <arm_group_label>CYP2C19*2 and CYP2C19*3 Variants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of participants has been genotyped to have the CYP2C19*2 and/or CYP2C19*3 variant during the first part of the study. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the wild-type CYP2C19 study subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wildtype CYP2C19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of participants has been genotyped to have wild-type CYP2C19. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the CYP2C19*2 and/or CYP2C19*3 study subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Limonene</intervention_name>
    <description>The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.</description>
    <arm_group_label>CYP2C19*2 and CYP2C19*3 Variants</arm_group_label>
    <arm_group_label>Wildtype CYP2C19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range: Greater than 18 years and less than 45 years.&#xD;
&#xD;
          -  Gender: Male or Female&#xD;
&#xD;
          -  Ethnicities: East Asian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or Breastfeeding&#xD;
&#xD;
          -  previous allergic reaction to limonene, citrus fruits, bovine gelatin, glycerin&#xD;
&#xD;
          -  past medical history of cerebrovascular or cardiovascular disease&#xD;
&#xD;
          -  veganism&#xD;
&#xD;
          -  history of chest pain or shortness of breath in the past month&#xD;
&#xD;
          -  certain medications that are CYP2C19 substrates or CYP2C19 inhibitors&#xD;
&#xD;
          -  Non-East Asian descent&#xD;
&#xD;
          -  age less than 18 y.o or age greater than 45 y.o&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Gross, MD/PhD</last_name>
    <phone>(650)721-4521</phone>
    <email>ergross@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Gross, MD/PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Eric Gross</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

